Combination chemotherapy with oral etoposide

David H. Johnson, John D. Hainsworth, Kenneth R. Hande, F. Anthony Greco

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Chronic administration of etoposide over multiple days has proved to be an effective schedule against a variety of neoplasms. The usual duration of etoposide administration is 3 to 5 days. However, recent studies have demonstrated this agent can be administered for up to 21 consecutive days with acceptable toxicity. Studies are currently under way to determine whether more protracted etoposide administration will prove to be more efficacious in the management of selected malignancies. Previous work at our institution has confirmed the activity of protracted administration of single-agent etoposide against small cell lung cancer and non-small cell lung cancer. More recently, we have combined either cisplatin or carboplatin with etoposide given orally for 21 consecutive days in phase II trials in patients with small cell lung cancer and non-small cell lung cancer. The results of these trials are reviewed.

Original languageEnglish (US)
Pages (from-to)19-24
Number of pages6
JournalSeminars in Oncology
Volume19
Issue number6 SUPPL. 14
StatePublished - 1992

Fingerprint

Etoposide
Combination Drug Therapy
Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
Carboplatin
Cisplatin
Neoplasms
Appointments and Schedules

ASJC Scopus subject areas

  • Oncology

Cite this

Johnson, D. H., Hainsworth, J. D., Hande, K. R., & Greco, F. A. (1992). Combination chemotherapy with oral etoposide. Seminars in Oncology, 19(6 SUPPL. 14), 19-24.

Combination chemotherapy with oral etoposide. / Johnson, David H.; Hainsworth, John D.; Hande, Kenneth R.; Greco, F. Anthony.

In: Seminars in Oncology, Vol. 19, No. 6 SUPPL. 14, 1992, p. 19-24.

Research output: Contribution to journalArticle

Johnson, DH, Hainsworth, JD, Hande, KR & Greco, FA 1992, 'Combination chemotherapy with oral etoposide', Seminars in Oncology, vol. 19, no. 6 SUPPL. 14, pp. 19-24.
Johnson DH, Hainsworth JD, Hande KR, Greco FA. Combination chemotherapy with oral etoposide. Seminars in Oncology. 1992;19(6 SUPPL. 14):19-24.
Johnson, David H. ; Hainsworth, John D. ; Hande, Kenneth R. ; Greco, F. Anthony. / Combination chemotherapy with oral etoposide. In: Seminars in Oncology. 1992 ; Vol. 19, No. 6 SUPPL. 14. pp. 19-24.
@article{da70e03c9f91413380fa18702d3728b5,
title = "Combination chemotherapy with oral etoposide",
abstract = "Chronic administration of etoposide over multiple days has proved to be an effective schedule against a variety of neoplasms. The usual duration of etoposide administration is 3 to 5 days. However, recent studies have demonstrated this agent can be administered for up to 21 consecutive days with acceptable toxicity. Studies are currently under way to determine whether more protracted etoposide administration will prove to be more efficacious in the management of selected malignancies. Previous work at our institution has confirmed the activity of protracted administration of single-agent etoposide against small cell lung cancer and non-small cell lung cancer. More recently, we have combined either cisplatin or carboplatin with etoposide given orally for 21 consecutive days in phase II trials in patients with small cell lung cancer and non-small cell lung cancer. The results of these trials are reviewed.",
author = "Johnson, {David H.} and Hainsworth, {John D.} and Hande, {Kenneth R.} and Greco, {F. Anthony}",
year = "1992",
language = "English (US)",
volume = "19",
pages = "19--24",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "6 SUPPL. 14",

}

TY - JOUR

T1 - Combination chemotherapy with oral etoposide

AU - Johnson, David H.

AU - Hainsworth, John D.

AU - Hande, Kenneth R.

AU - Greco, F. Anthony

PY - 1992

Y1 - 1992

N2 - Chronic administration of etoposide over multiple days has proved to be an effective schedule against a variety of neoplasms. The usual duration of etoposide administration is 3 to 5 days. However, recent studies have demonstrated this agent can be administered for up to 21 consecutive days with acceptable toxicity. Studies are currently under way to determine whether more protracted etoposide administration will prove to be more efficacious in the management of selected malignancies. Previous work at our institution has confirmed the activity of protracted administration of single-agent etoposide against small cell lung cancer and non-small cell lung cancer. More recently, we have combined either cisplatin or carboplatin with etoposide given orally for 21 consecutive days in phase II trials in patients with small cell lung cancer and non-small cell lung cancer. The results of these trials are reviewed.

AB - Chronic administration of etoposide over multiple days has proved to be an effective schedule against a variety of neoplasms. The usual duration of etoposide administration is 3 to 5 days. However, recent studies have demonstrated this agent can be administered for up to 21 consecutive days with acceptable toxicity. Studies are currently under way to determine whether more protracted etoposide administration will prove to be more efficacious in the management of selected malignancies. Previous work at our institution has confirmed the activity of protracted administration of single-agent etoposide against small cell lung cancer and non-small cell lung cancer. More recently, we have combined either cisplatin or carboplatin with etoposide given orally for 21 consecutive days in phase II trials in patients with small cell lung cancer and non-small cell lung cancer. The results of these trials are reviewed.

UR - http://www.scopus.com/inward/record.url?scp=0027095874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027095874&partnerID=8YFLogxK

M3 - Article

C2 - 1336896

AN - SCOPUS:0027095874

VL - 19

SP - 19

EP - 24

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 6 SUPPL. 14

ER -